- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.04. | Samsung BioLogics and Celltrion Get U.S. Tariff Relief | 2 | BusinessKorea | ||
| 07.04. | Celltrion's Truxima becomes first Korea-developed biosimilar to lead U.S. market | 1 | Korea Joongang Daily | ||
| 07.04. | Celltrion's Truxima becomes 1st Korean biosimilar to top U.S. prescriptions | 1 | Korea Herald | ||
| CELLTRION Aktie jetzt für 0€ handeln | |||||
| 07.04. | Celltrion's Truxima leads US prescription market in February | 1 | Korea Times | ||
| 07.04. | Celltrion's Truxima tops U.S. rituximab prescriptions | 1 | BusinessKorea | ||
| 07.04. | Celltrion's Truxima leads U.S. prescription market in Feb. | 1 | Yonhap News | ||
| 06.04. | Celltrion clears U.S. tariff overhang on new rules | 2 | Korea Herald | ||
| 01.04. | Celltrion to cancel 1.7 trillion won in treasury shares to boost shareholder value | 2 | Korea Joongang Daily | ||
| 01.04. | Celltrion retires W1.7tr shares in record cancellation | 1 | Korea Herald | ||
| 01.04. | Celltrion Cancels Treasury Shares Worth 1.7 Trillion Won | 1 | BusinessKorea | ||
| 01.04. | Celltrion to cancel 1.72 tln won in treasury shares to boost shareholder value | 3 | Yonhap News | ||
| 31.03. | Celltrion launches Omlyclo in Brazil, eyes Latin America growth | 5 | Korea Herald | ||
| 30.03. | Celltrion joins energy-saving push as oil prices climb | 2 | Korea Times | ||
| 27.03. | Celltrion accelerates Japan push with newly approved biosimilars | 1 | Korea Herald | ||
| 25.03. | Celltrion licenses in microbiome drug candidates from KoBioLabs | 3 | Korea Herald | ||
| 24.03. | Celltrion chairman says firm safe from global instability at shareholder meeting | 6 | Korea Joongang Daily | ||
| 24.03. | Celltrion ramps up capacity with W1.2tr Songdo investment | 1 | Korea Herald | ||
| 24.03. | Celltrion Invests 1.2 Trillion Won to Expand Songdo Production Infrastructure | 2 | BusinessKorea | ||
| 24.03. | Celltrion to invest $805 mil. for Incheon facility expansion | 1 | Korea Times | ||
| 24.03. | Celltrion to invest 1.2 tln won in S. Korea to meet rising demand | 2 | Yonhap News |
1 2 3 4 5 Weiter >>
114 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ERASCA | 16,310 | 0,00 % | Jefferies reiterates Erasca stock Buy rating on rival trial data | ||
| ALLOGENE THERAPEUTICS | 3,050 | 0,00 % | Allogene Therapeutics, Inc.: Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation ... | 41.6% Absolute Difference in the Cema-Cel Arm Over the Observation Arm Exceeded Clinically Meaningful Benchmark Based on Literature of 25-30%MRD Reduction Occurred Rapidly Following Cema-Cel Treatment... ► Artikel lesen | |
| BEAM THERAPEUTICS | 30,140 | 0,00 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 316,75 | 0,00 % | Praxis Precision Medicines: Raymond James sieht Kurspotenzial von über 150 % | ||
| QIAGEN | 36,070 | +2,04 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| NURIX THERAPEUTICS | 15,910 | 0,00 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update | Enrolling Phase 2 DAYBreak CLL-201 bexobrutideg trial designed to support Accelerated Approval in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Enabling Phase 3 DAYBreak CLL-306 bexobrutideg... ► Artikel lesen | |
| MAZE THERAPEUTICS | 27,420 | 0,00 % | Zifo Technologies: Zifo and Maze Therapeutics Partner to Power Precision Medicine | SAN FRANCISCO, Feb. 18, 2026 /PRNewswire/ -- Zifo, the leading global enabler of AI and data-driven enterprise informatics for science driven organizations and Maze Therapeutics Inc have... ► Artikel lesen | |
| CG ONCOLOGY | 67,67 | -0,04 % | CG Oncology, Inc. - 8-K, Current Report | ||
| TANGO THERAPEUTICS | 21,540 | 0,00 % | Leerink raises Tango Therapeutics stock price target on PDAC data | ||
| ADMA BIOLOGICS | 10,370 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research | Short seller's Characterization of ASCENIV's Competitive Position Reflects Blatant Misunderstanding of ADMA's Business and Its Role as Late-line Therapy for Patients Who are Immune Compromised and... ► Artikel lesen | |
| EVOTEC | 5,180 | +10,21 % | Evotec: Aktivistischer Investor macht Druck - die Hintergründe | Die Aktie des Hamburger Wirkstoffforschers Evotec hat den Anlegern in den zurückliegenden Jahren nur wenig Freude bereitet. Der Titel rutschte sogar vor kurzem auf ein neues Mehrjahrestief ab. Das ruft... ► Artikel lesen | |
| COGENT BIOSCIENCES | 36,500 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST) | Bezuclastinib NDA submitted under the FDA's RTOR program based on positive results from Phase 3 PEAK trial; bezuclastinib previously granted Breakthrough Therapy Designation in GISTBezuclastinib combination... ► Artikel lesen | |
| TYRA BIOSCIENCES | 35,610 | 0,00 % | Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights | - Launched "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH, 3 potential blockbuster indications -
- Interim Ph2... ► Artikel lesen | |
| COMPASS THERAPEUTICS | 5,200 | 0,00 % | Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update | In the Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer, the prespecified event threshold of 80% overall survival (OS) events was... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 88,51 | 0,00 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma | KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027 KT-621 BROADEN2 Phase 2b atopic dermatitis (AD) trial ongoing, with data expected by mid-2027 Fast Track... ► Artikel lesen |
CELLTRION INC gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CELLTRION INC finden Sie auf Wallstreet Online.